Loading...

Northwest Biotherapeutics

OTCPK:NWBO
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NWBO
OTCPK
$186M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Northwest Biotherapeutics has significant price volatility in the past 3 months.
NWBO Share Price and Events
7 Day Returns
2.1%
OTCPK:NWBO
2.3%
US Biotechs
1.6%
US Market
1 Year Returns
41.7%
OTCPK:NWBO
-4%
US Biotechs
2.6%
US Market
NWBO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Northwest Biotherapeutics (NWBO) 2.1% 25.9% 41.7% 41.7% -59.3% -94.5%
US Biotechs 2.3% -0.6% -5.4% -4% 7.5% 12.9%
US Market 1.6% -1.7% 2.1% 2.6% 38.5% 41.4%
1 Year Return vs Industry and Market
  • NWBO outperformed the Biotechs industry which returned -4% over the past year.
  • NWBO outperformed the Market in United States of America which returned 2.6% over the past year.
Price Volatility
NWBO
Industry
5yr Volatility vs Market

Value

 Is Northwest Biotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Northwest Biotherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Northwest Biotherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Northwest Biotherapeutics. This is due to cash flow or dividend data being unavailable. The share price is $0.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Northwest Biotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Northwest Biotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:NWBO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.09
OTCPK:NWBO Share Price ** OTCPK (2019-05-21) in USD $0.34
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.74x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Northwest Biotherapeutics.

OTCPK:NWBO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:NWBO Share Price ÷ EPS (both in USD)

= 0.34 ÷ -0.09

-3.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Northwest Biotherapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Northwest Biotherapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Northwest Biotherapeutics's expected growth come at a high price?
Raw Data
OTCPK:NWBO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.23x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Northwest Biotherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Northwest Biotherapeutics's assets?
Raw Data
OTCPK:NWBO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.11
OTCPK:NWBO Share Price * OTCPK (2019-05-21) in USD $0.34
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.32x
United States of America Market PB Ratio Median Figure of 5,202 Publicly-Listed Companies 1.84x
OTCPK:NWBO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:NWBO Share Price ÷ Book Value per Share (both in USD)

= 0.34 ÷ -0.11

-3.12x

* Primary Listing of Northwest Biotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Northwest Biotherapeutics has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of NWBO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Northwest Biotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Northwest Biotherapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Northwest Biotherapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Northwest Biotherapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Northwest Biotherapeutics expected to grow at an attractive rate?
  • Unable to compare Northwest Biotherapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Northwest Biotherapeutics's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Northwest Biotherapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:NWBO Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:NWBO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:NWBO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:NWBO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -40 -43
2018-12-31 0 -35 -54
2018-09-30 1 -35 -76
2018-06-30 1 -37 -108
2018-03-31 0 -29 -93
2017-12-31 0 -36 -74
2017-09-30 0 -36 -77
2017-06-30 0 -40 -86
2017-03-31 0 -50 -92
2016-12-31 1 -56 -86
2016-09-30 1 -65 -79
2016-06-30 2 -67 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Northwest Biotherapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Northwest Biotherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:NWBO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Northwest Biotherapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NWBO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:NWBO Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.09
2018-12-31 -0.12
2018-09-30 -0.20
2018-06-30 -0.31
2018-03-31 -0.32
2017-12-31 -0.31
2017-09-30 -0.39
2017-06-30 -0.56
2017-03-31 -0.73
2016-12-31 -0.77
2016-09-30 -0.78
2016-06-30 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Northwest Biotherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of NWBO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Northwest Biotherapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Northwest Biotherapeutics's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Northwest Biotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Northwest Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Northwest Biotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Northwest Biotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Northwest Biotherapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Northwest Biotherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Northwest Biotherapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Northwest Biotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Northwest Biotherapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NWBO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.62 -42.90 27.90
2018-12-31 0.41 -53.56 27.02
2018-09-30 0.90 -76.17 29.76
2018-06-30 0.59 -107.85 28.84
2018-03-31 0.40 -93.39 18.78
2017-12-31 0.34 -74.41 21.50
2017-09-30 0.38 -76.85 21.27
2017-06-30 0.39 -85.81 21.29
2017-03-31 0.46 -92.38 22.47
2016-12-31 0.62 -85.86 19.81
2016-09-30 1.42 -79.23 21.01
2016-06-30 1.55 -24.38 20.80
2016-03-31 1.78 -74.41 25.78
2015-12-31 1.74 -114.74 24.90
2015-09-30 1.75 -133.35 24.11
2015-06-30 2.04 -177.01 24.23
2015-03-31 1.65 -136.03 16.67
2014-12-31 1.45 -135.63 16.96
2014-09-30 0.58 -109.84 15.61
2014-06-30 0.40 -111.71 14.18
2014-03-31 0.67 -97.44 13.59
2013-12-31 0.81 -65.79 12.38
2013-09-30 1.13 -79.42 16.34
2013-06-30 0.85 -73.01 17.20
2013-03-31 0.91 -71.56 15.96
2012-12-31 0.77 -67.32 15.68
2012-09-30 0.45 -49.37 10.81
2012-06-30 0.34 -32.40 9.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Northwest Biotherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Northwest Biotherapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Northwest Biotherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Northwest Biotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Northwest Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Northwest Biotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Northwest Biotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Northwest Biotherapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Northwest Biotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Northwest Biotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Northwest Biotherapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Northwest Biotherapeutics Company Filings, last reported 1 month ago.

OTCPK:NWBO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -58.50 23.07 16.29
2018-12-31 -47.16 16.80 22.22
2018-09-30 -47.14 31.88 0.25
2018-06-30 -63.79 32.79 1.60
2018-03-31 -63.03 31.73 0.20
2017-12-31 -47.29 31.43 0.12
2017-09-30 -42.83 27.00 1.05
2017-06-30 -35.24 32.03 0.02
2017-03-31 -36.64 33.52 1.84
2016-12-31 -26.50 31.71 6.19
2016-09-30 -5.02 21.09 0.80
2016-06-30 -18.97 22.14 2.14
2016-03-31 -6.19 22.68 11.69
2015-12-31 -4.68 22.81 21.81
2015-09-30 -57.36 22.78 5.39
2015-06-30 -76.17 24.90 19.20
2015-03-31 -70.70 30.17 3.17
2014-12-31 -35.03 23.68 13.39
2014-09-30 -31.22 18.67 1.40
2014-06-30 -29.87 1.17 8.85
2014-03-31 -31.06 1.17 12.23
2013-12-31 -9.82 1.22 18.50
2013-09-30 -25.08 1.60 2.86
2013-06-30 -27.25 2.28 1.99
2013-03-31 -28.05 3.42 0.37
2012-12-31 -16.07 3.87 7.35
2012-09-30 -38.10 22.16 0.11
2012-06-30 -30.66 20.29 0.43
  • Northwest Biotherapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Northwest Biotherapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Northwest Biotherapeutics has less than a year of cash runway based on current free cash flow.
  • Northwest Biotherapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -34.3% each year.
X
Financial health checks
We assess Northwest Biotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Northwest Biotherapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Northwest Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Northwest Biotherapeutics dividends.
If you bought $2,000 of Northwest Biotherapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Northwest Biotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Northwest Biotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:NWBO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:NWBO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Northwest Biotherapeutics has not reported any payouts.
  • Unable to verify if Northwest Biotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Northwest Biotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Northwest Biotherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Northwest Biotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Northwest Biotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Northwest Biotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Northwest Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Linda Powers
COMPENSATION $7,200,000
AGE 62
TENURE AS CEO 7.9 years
CEO Bio

Ms. Linda F. Powers, J.D., has been the Chief Executive Officer and President of Northwest Biotherapeutics, Inc. since June 8, 2011 and also serves as its Chief Financial Officer and Accounting Officer. Ms. Powers has served as the Chairperson of Board of Directors of Northwest Biotherapeutics, Inc. since May 17, 2007. Ms. Powers served as Managing Director of Toucan Capital Corp. and Toucan Capital Fund II, L.P from 2001 to 2010 and Toucan Capital Fund III thereafter. She is a Co-Founder of Toucan Capital Corp. and Toucan Capital Fund II, L.P. She has more than 25 years of experience in the fields of venture capital, public-private partnerships, corporate finance and restructurings, mergers and acquisitions, joint ventures, IP licensing and highly leveraged, structured and specialty finance transactions and more than six years of experience in seed and early stage venture capital investing. Prior to Toucan Capital, she served as Senior Vice President of Global Finance at Enron Corp. Prior to joining Enron, she served as a Deputy Assistant Secretary of Commerce in the Bush Administration from 1989 to 1993. In that capacity, she was responsible for a number of small business programs, mainly concerned with access to capital. She also assisted financial services, information services and related businesses in entering foreign markets and was responsible for government to government negotiations to remove foreign market entry restrictions for U.S. firms. In addition, Ms. Powers served as a co-lead negotiator for United States on the North American Free Trade Agreement and financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico. During 1980’s, she practiced law, specializing in corporate mergers, acquisitions and financings and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules, which now govern know how licensing in the European Union. Ms. Powers has been the Chairperson and Director of Northwest Biotherapeutics, Inc. since May 17, 2007. She has been Director of Vet-Stem, Inc. since 2019. She has been a Director of Q Holdings, Inc. (formerly Grace 2, Inc.) since October 13, 2011. She serves as a Director of Pepgen Corporation and Moffitt Genetics Corporation, Inc. Ms. Powers served as Director of Q Therapeutics, Inc. from April 2004 to December 11, 2015. She served as a Director of Reactive NanoTechnologies, Inc. She serves as a Trustee of Trudeau Institute, Inc. She serves on the Steering Committee at the National Academy of Sciences, evaluating Federal grant programs and on the Advisory Board at the U.S. Department of Commerce NIST Advanced Technology Program. She has served for several years on the Technology Advisory Board of the Moffitt Cancer Center in Tampa. Ms. Powers also served on the Investment Board of Maryland's state-run seed and early stage venture capital fund. Over seven years, she has become a recognized leader in the stem cell industry nationwide in the United States, as well as in Europe, India and China and has served as the Chair of Maryland's Stem Cell Commission, where she was responsible for administering the state's stem cell research funding for the first two years of the program. She has been appointed to key technology and industry commissions by the Governors of two states. Her board service includes various public boards including the Virginia Research and Technology Advisory Committee, the Advisory Board of the U.S. National Institutes of Standards and Technology's Advanced Technology Program. Ms. Powers served on the Maryland Governor's Commission on the Development of Advanced Technology Businesses and Maryland's Enterprise Investment Fund. She co-teaches a course on Entrepreneurship for Scientists at the National Institute of Health for six years and has taught International Business Transactions and European Business Law as an Adjunct Professor at Georgetown Law School for eight years. Ms. Powers received a J.D. degree, magna cum laude, from Harvard Law School. She holds a B.A. in Economics from Woodrow Wilson School, Princeton University, where Ms. Powers graduated magna cum laude and Phi Beta Kappa. Ms. Powers is a Board member of M2GEN (an affiliate of Moffitt Cancer Center), the Chinese Biopharmaceutical Association, and the Rosalind Franklin Society. For more than six years, Ms. Powers taught an annual internal course at the National Institutes of Health for the bench scientists and technology transfer personnel on the development and commercialization of medical products. Ms. Powers serves on the boards of several private biotechnology companies.

CEO Compensation
  • Linda's compensation has increased whilst company is loss making.
  • Linda's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Northwest Biotherapeutics management team in years:

9.6
Average Tenure
66
Average Age
  • The average tenure for the Northwest Biotherapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Linda Powers

TITLE
Chairperson
COMPENSATION
$7M
AGE
62
TENURE
7.9 yrs

Alton Boynton

TITLE
Founder
COMPENSATION
$2M
AGE
73
TENURE
21.3 yrs

Marnix Bosch

TITLE
Chief Technical Officer
COMPENSATION
$635K
AGE
59
TENURE
12.3 yrs

Les Goldman

TITLE
Senior VP & General Counsel
COMPENSATION
$5M
AGE
73

David Innes

TITLE
Vice President of Investor Relations
TENURE
0.3 yrs

Anthony Maida

TITLE
Senior Vice President of Clinical Research
COMPENSATION
$300K
AGE
66
TENURE
5.3 yrs

Pankaj Shah

TITLE
Financial Controller
TENURE
11.3 yrs
Board of Directors Tenure

Average tenure and age of the Northwest Biotherapeutics board of directors in years:

13.7
Average Tenure
66.5
Average Age
  • The average tenure for the Northwest Biotherapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Alton Boynton

TITLE
Founder
COMPENSATION
$2M
AGE
73
TENURE
21.3 yrs

Linda Liau

TITLE
Chairman of Clinical Advisory Board
TENURE
13.7 yrs

Linda Powers

TITLE
Chairperson
COMPENSATION
$7M
AGE
62
TENURE
12 yrs

Jerry Jasinowski

TITLE
Lead Independent Director
COMPENSATION
$987K
AGE
79

Tom Mikkelsen

TITLE
Member of Clinical Advisory Board
TENURE
13.7 yrs

Steven Brem

TITLE
Member of Clinical Advisory Board
TENURE
13.7 yrs

Darell Bigner

TITLE
Member of Clinical Advisory Board
TENURE
13.7 yrs

Henry Brem

TITLE
Member of Clinical Advisory Board
AGE
65
TENURE
13.7 yrs

Navid Malik

TITLE
Director
COMPENSATION
$2M
AGE
49
TENURE
7.1 yrs

J. Black

TITLE
Independent Director
COMPENSATION
$443K
AGE
68
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
30. Jan 19 Sell Linda Powers Individual 27. Dec 18 27. Dec 18 -3,558,639 $0.17 $-604,969
30. Jan 19 Sell Toucan Capital Corp. Company 28. Dec 18 28. Dec 18 -804,146 $0.17 $-136,705
X
Management checks
We assess Northwest Biotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Northwest Biotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Details
Name: Northwest Biotherapeutics, Inc.
NWBO
Exchange: OTCPK
Founded: 1996
$185,937,418
546,874,761
Website: http://www.nwbio.com
Address: Northwest Biotherapeutics, Inc.
4800 Montgomery Lane,
Suite 800,
Bethesda,
Maryland, 20814,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK NWBO Common Stock Pink Sheets LLC US USD 14. Dec 2001
BST NBYB Common Stock Boerse-Stuttgart DE EUR 14. Dec 2001
LSE 0K95 Common Stock London Stock Exchange GB EUR 14. Dec 2001
Number of employees
Current staff
Staff numbers
14
Northwest Biotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 03:33
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2017/04/17
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.